HLA-G and neoplasm: So far, dociparstat showed limited efficacy as monotherapy, but we may speculate that its combined administration with different anti-TIM-3 antibodies, already approved for clinical purposes, plus anti-HLA-G antibodies may result in increased anti-tumor efficacy.